Apologies Stezza, I meant to type FDA not TGA in my last sentence. Can't seem to edit it! Yes, I agree that TGA approval will give Colostat more credit with potential CLIA lab partners. Still, Colvera managed fine without it.
Possibly whatever deal is struck with a US company, there might be implications for the Australian market deals... so perhaps Rhythm themselves are holding off committing to anything there yet, until they know what is happening in Australia?
RHY Price at posting:
$1.06 Sentiment: Buy Disclosure: Held
